Amgen VP reports 327-share tax withholding

Amgen Inc. vice president, finance and chief accounting officer Matthew C. Busch reported a small tax-related share disposition.

Rhea-AI Filing Summary

Amgen Inc. vice president, finance and chief accounting officer Matthew C. Busch reported a small tax-related share disposition. On the reported date, 327 shares of Amgen common stock were withheld at a price of $366.21 per share to satisfy tax obligations, classified as a tax-withholding disposition rather than an open-market sale.

After this transaction, Busch directly held 4,048 shares of Amgen common stock. His holdings include 68 dividend equivalents credited under Amgen’s equity incentive plan, which will be paid out in common shares as related restricted stock units vest.

Insider Trade Summary

Exercise Price or Tax Liability: 327 shares

Exercise Price or Tax Liability 1 txn

Insider Busch Matthew C.

Role VP, Finance & CAO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	327	$366.21	$120K

Holdings After Transaction: Common Stock — 4,048 shares (Direct)

Footnotes (1)

1. F1. These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amgen (AMGN) executive Matthew C. Busch report in this Form 4 filing?

Matthew C. Busch reported a tax-related share disposition involving 327 Amgen common shares. These shares were withheld to satisfy tax liabilities, not sold on the open market, and the transaction reflects routine administration of his equity compensation rather than a discretionary trade.

How many Amgen (AMGN) shares were involved in Matthew C. Busch’s tax-withholding transaction?

The filing shows 327 Amgen common shares were used in a tax-withholding disposition at a price of $366.21 per share. This means the shares were delivered to cover tax obligations arising from equity awards, rather than being sold for investment or portfolio reasons.

How many Amgen (AMGN) shares does Matthew C. Busch hold after this Form 4 transaction?

After the tax-withholding event, Matthew C. Busch directly holds 4,048 Amgen common shares. This total includes his remaining equity position following the 327-share disposition and reflects his ongoing ownership stake as vice president, finance and chief accounting officer at the company.

Are dividend equivalents included in Matthew C. Busch’s Amgen (AMGN) share holdings?

Yes. The filing notes that Busch’s holdings include 68 dividend equivalents granted under Amgen’s equity incentive plan. These dividend equivalents are tied to unvested restricted stock units and will be paid out in Amgen common shares according to the awards’ vesting schedule.

Was Matthew C. Busch’s Amgen (AMGN) Form 4 transaction an open-market sale?

No. The Form 4 characterizes the 327-share transaction as a tax-withholding disposition. Shares were delivered to satisfy tax liabilities associated with equity compensation, rather than being sold in the open market as a discretionary buy or sell decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 08:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Busch Matthew C.

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Finance & CAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		F		327	D	$366.21	4,048(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Matthew C. Busch	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)